Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05884-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Yu Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, CCAAT-Enhancer-Binding Proteins, Mutation. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Medical Research Foundation of Guangdong Province, President Foundation of The Third Affiliated Hospital of Southern Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Biallelic mutations of the CEBPA gene (CEBPAbi) are generally associated with favorable prognosis in patients with acute myeloid leukemia (AML). Monoallelic mutations of the CEBPA gene in carboxy-terminal DNA-binding region (CEBPAsmbZIP) and amino-terminal transactivation domains (CEBPAsmTAD) indicate distinct clinical characteristics and therapeutic outcomes. However, further investigation is required to fully understand these differences. In this retrospective study, we enrolled 77 AML patients with CEBPA mutations, including 53 with CEBPAbi, 12 with CEBPAsmbZIP and 12 with CEBPAsmTAD. The clinical characteristics of the three CEBPAmut groups presented significant differences in age, FAB classification, hemoglobin level and platelet count at diagnosis. The CEBPAsmTAD group exhibited shorter 2-year overall survival (OS) and relapse-free survival (RFS) compared to the CEBPAbi group and CEBPAsmbZIP group in AML patients. The most common co-mutations observed in CEBPAmut AML patients were TET2 and GATA2, which had no effect on prognosis. 2-year RFS of 27 CEBPAmut AML patients who underwent allo-HSCT was better than those who did not. MRD3 positive was identified as an influencing factor for 2-year OS and RFS. Allo-HSCT was found to improve the prognosis of CEPBAmut AML patients with positive MRD3 and adverse co-mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
- Department of Hematology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, 510630, China.
- Department of Hematology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, China. jiajun.l@163.com.
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China. jxj3331233@163.com.
Förderung
- Medical Research Foundation of Guangdong Province
- President Foundation of The Third Affiliated Hospital of Southern Medical University
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Zhao, Y., Huang, Y., Jiang, L., Zhang, Y., Liu, F., Yan, P., Yu, G., Liu, J., & Jiang, X. (2024). Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05884-9
Vancouver
Zhao Y, Huang Y, Jiang L, Zhang Y, Liu F, Yan P, et al. Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05884-9
BibTeX
@article{Zhao2024,
author = {Zhao, Yu and Huang, Yun and Jiang, Ling and Zhang, Yujiao and Liu, Fang and Yan, Ping and Yu, Guopan and Liu, Jiajun and Jiang, Xuejie},
title = {Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05884-9}
}
EUVIMED